M1Pram – ADOCIA a biotechnology company dedicated to protein delivery
Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus
Diabetes mellitus Typ 1: Add-on-Therapie zu Insulin im Blick
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
GLP-1 Agonists in Type 1 Diabetes Mellitus | Semantic Scholar
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes | Nature Reviews Nephrology
Current Management of Glycemia in Children with Type 1 Diabetes Mellitus | NEJM
A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism - ScienceDirect
GLP-1: Actions on Beta-cell Mass and Function
Glucagon-like Peptide (GLP-1) and the treatment of diabetes - YouTube
Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control | Hypertension
Frontiers | GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Medikamente gegen Typ-2-Diabetes: GLP-1-Analoga | Apotheken Umschau
Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes, the ADJUNCT ONE™ treat-to-target randomised trial - Media Centre | EASD
How Does GLP-1 Affect Diabetes?
Glucagon-like Peptide-1 Plasmid Construction and Delivery for the Treatment of Type 2 Diabetes: Molecular Therapy
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors | The Review of Diabetic Studies
Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity - Bisgaard Bengtsen - 2021 - Physiological Reports - Wiley Online Library
2 Medikamentöse Therapie des Glukosestoffwechsels — Leitlinien.de
GLP-1-Rezeptoragonisten (Inkretinmimetika) | Gelbe Liste
